A novel deletion at codon 441 of the APC gene associated with ophthalmic lesions (CHRPE) in a South African family

Johanna J Grobbelaar, Ari Ziskind, Greetje de Jong, C J Joubert Oosthuizen, Maritha J Kotze

Department of Human Genetics, Faculty of Medicine, University of Stellenbosch, PO Box 19063, Tygerberg 7505, South Africa
J J Grobbelaar
G de Jong
C J J Oosthuizen
M J Kotze

Received 27 September 1995
Revised version accepted for publication 11 December 1995

Abstract
A novel mutation at codon 441 in exon 10 of the adenomatous polyposis coli (APC) gene was identified in a South African family of mixed ancestry, using a convenient, non-radioactive, heteroduplex-SSCP screening assay. This single thymidine deletion after nucleotide position 1322 creates a frameshift resulting in a downstream stop codon at amino acid residue 453 of the APC gene. Genotypes of nine family members were subsequently correlated with the presence or absence of congenital hypertrophy of the retinal pigment epithelium (CHRPE), since expression of this common extracolonic manifestation of FAP is largely determined by the length of the truncated protein. CHRPE was absent in the five unaffected family members analysed, while four mutation positive subjects showed these ophthalmic lesions. Correlation between the molecular analysis and ophthalmic examinations, performed without knowledge of clinical and genetic status respectively, provided additional evidence in favour of the view that the range of phenotypic expression in FAP may result from different allelic manifestations of APC mutations.

Key words: familial adenomatous polyposis coli; ophthalmic lesions (CHRPE); frameshift mutation.

Mutations in the adenomatous polyposis coli (APC) gene cause the autosomal dominant disease familial adenomatous polyposis (FAP). Congenital hypertrophy of the retinal pigment epithelium (CHRPE) is clinically the most common and most reliable extracolonic manifestation of FAP and has been shown to be present in patients with mutations in codons 457–1387 of the APC gene. Patients with mutations in codons 136–302 and beyond codon 1444 regularly do not develop CHRPE, while patients with mutations in codons 413–437 have an intermediate CHRPE score. The expression of ophthalmic lesions can thus potentially be used to restrict mutation screening in a subset of clinically diagnosed FAP patients to a specific region of the APC gene. In this study we identified a novel mutation at codon 441 in exon 10 of the APC gene and showed that this allelic site is associated with the presence of CHRPE.

Methods
Genomic DNA was extracted from 17 apparently unrelated South African FAP patients, PCR amplified according to Miyoshi et al., and screened for mutations in exon 10 (codon 439–470) of the APC gene by combined heteroduplex-SSCP analysis, as described by Kotze et al. Segregation analysis was subsequently performed using genomic DNA ex-

Figure 1 Identification of a 1 bp deletion at codon 441 of the APC gene. (A) Heteroduplex-SSCP analysis of PCR products from 17 FAP patients in a 10% (2.5x cross linked) polyacrylamide gel supplemented with 7.5% urea and stained with ethidium bromide. In lane 11 the PCR amplified DNA of one index patient shows aberrant single (upper bands) and double stranded (lower bands) conformational polymorphisms. Homoduplex (solid arrows) and heteroduplex (broken arrows) bands observed in the double stranded DNA are indicated on the right side of the gel. (B) Direct DNA sequencing of the patient showing the aberrant bands in lane 11.
A novel deletion at codon 441 of the APC gene

Figure 2  Pedigree of the index patient (marked by an arrow) with the 1 bp deletion. Dark shaded symbols represent clinically diagnosed FAP patients. Subjects who underwent colectomies, DNA screening, and indirect ophthalmoscopy are indicated with + for presence and − for absence of the respective parameters. NA = not analysed; CHRPE = congenital hypertrophy of the retinal pigment epithelium.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Subjects</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Subjects III1 showed that four subjects DNA mutations in after nucleotide one formed the patient (marked by an arrow)</td>
</tr>
<tr>
<td></td>
<td>To the date, the mutation/CHRPE positive subjects III-1 (10 years) and III-9 (6 years) have not shown any clinical symptoms. The five mutation negative subjects (II-10, II-3, II-6, III-7, and III-8) did not present with CHRPE lesions.</td>
</tr>
</tbody>
</table>

Results

In one of the 17 FAP patients screened for mutations in exon 10 of the APC gene (fig 1A), a single thymidine deletion was identified after nucleotide position 1322 at codon 441 (fig 1B). Mutation screening of PCR amplified DNA obtained from 15 family members of the index patient (II-1) showed that six additional subjects inherited the single nucleotide deletion (fig 2). Indirect ophthalmoscopy performed on the index patient and eight family members showed that four subjects had CHRPE lesions (table). To date, the mutation/CHRPE positive subjects III-1 (10 years) and III-9 (6 years) have not shown any clinical symptoms. The five mutation negative subjects (II-10, II-3, II-6, III-7, and III-8) did not present with CHRPE lesions.

Discussion

A novel single nucleotide deletion (T) at codon 441 of the APC gene was identified in a South African family. This frameshift mutation created a downstream stop codon at a position corresponding to amino acid residue 453. The truncated APC protein, predicted to result from this alteration, probably underlies the FAP phenotype in the index patient and his affected family members. Cosegregation of the mutation with the FAP phenotype was shown in three generations. The previously described relationship between the site of APC mutation and phenotypic expression of CHRPE,7-10 was subsequently studied in the South African family. As expected, all the mutation positive subjects identified in this study, who could be traced and were subjected to ophthalmic examinations, showed the CHRPE phenotype. Those that did not inherit the deleted allele were CHRPE negative, thus confirming the intrafamilial CHRPE correlation.

The majority of FAP related mutations identified worldwide, including all the mutations identified to date in South Africa,11 are frameshifts resulting in truncated proteins. Consistent findings that the expression of CHRPE is largely determined by the length of the mutant APC protein product, therefore, have important diagnostic implications with respect to facilitating the detection of FAP related mutations. The screening of the entire coding region of the APC gene for mutation detection in order to provide diagnostic reliability can now be narrowed down to specific gene regions in cases examined ophthalmoscopically.

We are grateful to the FAP patients and their families. This work was supported by the National Cancer Association of South Africa, the University of Stellenbosch, and the Administration, Western Cape.


